Aroa BiosurgeryASX:ARX +0.85%62 Market Cap is A$204.59 Mil as of Jun. 27, 2026. GuruFocus rates ASX:ARX with a GF Score™ of 62/100 and a GF Value™ of A$0.80 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 866 Medical Devices & Instruments companies, Aroa Biosurgery ranks better than 52.42% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Aroa Biosurgery's share price for the quarter that ended in Mar. 2026 was A$0.595. Aroa Biosurgery's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 345.48 Mil. Therefore, Aroa Biosurgery's market cap for the quarter that ended in Mar. 2026 was A$205.56 Mil.
Aroa Biosurgery's quarterly market cap
increased
from Mar. 2025 (A$146.58 Mil) to Sep. 2025 (A$224.27 Mil) but then
declined
from Sep. 2025 (A$224.27 Mil) to Mar. 2026 (A$205.56 Mil).
Aroa Biosurgery's annual market cap
declined
from Mar. 2024 (A$191.04 Mil) to Mar. 2025 (A$146.58 Mil) but then
increased
from Mar. 2025 (A$146.58 Mil) to Mar. 2026 (A$205.56 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Aroa Biosurgery's Enterprise Value for Today is A$187.34 Mil.
Aroa Biosurgery (ASX:ARX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Aroa Biosurgery Market Cap Related Terms
Aroa Biosurgery Market Cap Historical Data
* Premium members only.
The historical data trend for Aroa Biosurgery's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Aroa Biosurgery's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aroa Biosurgery Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's Market Cap distribution charts can be found below:
* The bar in red indicates where Aroa Biosurgery's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Aroa Biosurgery's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aroa Biosurgery (ASX:ARX) has a Market Cap of A$204.59 Mil as of Jun. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Aroa Biosurgery and its competitors. According to the industry distribution chart, Aroa Biosurgery ranks #412 out of 866 companies in the Medical Devices & Instruments industry, placing it in the top 47.6%.
Is Aroa Biosurgery's Market Cap too high?
Aroa Biosurgery's current Market Cap is A$204.59 Mil. Based on the distribution chart, Aroa Biosurgery ranks #412 out of 866 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Aroa Biosurgery has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aroa Biosurgery ranks #412 out of 866 companies for Market Cap. This puts Aroa Biosurgery in the upper half of its industry. The industry median Market Cap is 121.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 121.29, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Aroa Biosurgery and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 121.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aroa Biosurgery's current Market Cap is A$204.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.80, compared to a current price of A$0.59 — trading 26.3% below its estimated fair value. The current Market Cap is A$204.59 Mil. Aroa Biosurgery's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current Market Cap is A$204.59 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?
Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued.
The current stock price of A$0.59 is trading 26.3% below its estimated GF Value™ of A$0.80.
GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.
Key valuation signals for ASX:ARX:
Market Cap: A$204.59 Mil
GF Value™: A$0.80 vs. price of A$0.59 (26.3% below fair value)
No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
62GF Score
Get the complete analysis for ASX:ARX
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ARX has been successfully added to your 
